Attached files
| file | filename |
|---|---|
| 10-K - Talon Therapeutics, Inc. | v177968_10k.htm |
| EX-3.1 - Talon Therapeutics, Inc. | v177968_ex3-1.htm |
| EX-23.1 - Talon Therapeutics, Inc. | v177968_ex23-1.htm |
| EX-31.1 - Talon Therapeutics, Inc. | v177968_ex31-1.htm |
| EX-31.2 - Talon Therapeutics, Inc. | v177968_ex31-2.htm |
Exhibit
32.1
CERTIFICATIONS
PURSUANT TO
18 U.S.C.
SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE
SARBANES-OXLEY ACT OF 200 2
Pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, each of the undersigned officers of Hana
Biosciences, Inc. do hereby certify that to the best of his
knowledge:
(a) the
Annual Report on Form 10-K of Hana Biosciences, Inc. for the year ended December
31, 2009 (the “Report”) fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and
(b)
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of Hana Biosciences,
Inc.
|
Dated:
March 25, 2010
|
By:
|
/s/
Steven R. Deitcher
|
|
Steven
R. Deitcher, M.D.
|
||
|
President
& Chief Executive
Officer
|
|
Dated:
March 25, 2010
|
By:
|
/s/
Tyler M. Nielsen
|
|
Tyler
M. Nielsen
|
||
|
Interim
Vice President, Chief Financial
Officer
|